<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">596</article-id><article-id pub-id-type="doi">10.17650/2686-9594-2023-13-1-45-53</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Percutaneous irreversible electroporation in locally advanced pancreatic cancer – a review and a case report</article-title><trans-title-group xml:lang="ru"><trans-title>Чрескожная необратимая электропорация при местно-распространенном раке поджелудочной железы – обзор литературы и клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Polyakov</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Поляков</surname><given-names>А. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexandr nikolaevich Polyakov</p><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p>Александр Николаевич Поляков</p><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><email>dr.alexp@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Patyutko</surname><given-names>Yu. I.</given-names></name><name xml:lang="ru"><surname>Патютко</surname><given-names>Ю. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pogrebnyakov</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Погребняков</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dolgushin</surname><given-names>B. I.</given-names></name><name xml:lang="ru"><surname>Долгушин</surname><given-names>Б. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sholohov</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Шолохов</surname><given-names>В. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vlasenko</surname><given-names>O. S.</given-names></name><name xml:lang="ru"><surname>Власeнко</surname><given-names>О. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bazin</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Базин</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kantieva</surname><given-names>D. M.</given-names></name><name xml:lang="ru"><surname>Кантиева</surname><given-names>Д. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Romanova</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Романова</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozhushkov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Кожушков</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozhushkov</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Кожушков</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Podluzhnyi</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Подлужный</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-04-21" publication-format="electronic"><day>21</day><month>04</month><year>2023</year></pub-date><volume>13</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>45</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2023-04-21"><day>21</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-04-21"><day>21</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, АБВ-пресс</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://onco-surgery.info/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/596">https://onco-surgery.info/jour/article/view/596</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> The results of local destruction methods in locally advanced pancreatic cancer (LAPCa) are contradictory. Radiation therapy is the most commonly used. Other methods are used much less frequently, irreversible electroporation (IRE) is one of them. Most authors indicate an acceptable level of complications and mortality, but without an improvement in long-term results. The results of two meta-analyses have been published, the authors indicate the possibility of using the IRE in selected patients. The authors also point out that minimally invasive methods of using the IRE be preferred. Some experience has been gained in the use of percutaneous access for IRE in LAPCa. Computed tomography, ultrasound guidance can be used for navigation. The level of complications can reach 50 %. Mortality with percutaneous access, as a rule, is absent or does not exceed 5 %. Long-term results are the same with the results of open IRE.</p><p><bold>Aim.</bold> To share authors experience of using percutaneous irreversible electroporation in pancreatic cancer, because there are no references to the use of percutaneous IRE in LAPCa in Russia.</p><p><bold>Materials and methods.</bold> The IRE was performed for 53-year female patient with LAPCa after successful induction therapy. A step-by-step pulse effect of electrodes installed under ultrasound control on the tumor infiltrate was carried out. Magnetic resonance imaging, computed tomography and other types of studies were used for diagnostic purposes.</p><p><bold>Results.</bold> The involvement of the common hepatic artery and portal vein remained after the induction therapy, which did not allow performing pancreatoduodenal resection. Ultrasonic navigation and flat-detector computed tomography allowed to install the electrodes adequatly and safely. The impact zone almost completely blocked the infiltrate zone, a more optimal location of the electrodes was limited by the wide network of venous collaterals. Magnetic resonance imaging data performed before and after the procedure showed no progression of the disease within more than three months after the procedure, including in the affected area. Tumor shrinkage was noted as a partial response.</p><p><bold>Conclusion.</bold> The first experience confirmed the safety and the absence of subsequent complications when using the percutaneous access method of IRE for LAPCa. Follow-up monitoring of the patient will allow to say more correctly about the possibility of the method to provide long-term local control.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. Результаты применения методов локального воздействия при местно-распространенном раке поджелудочной</bold> железы (МРРПЖ) противоречивы, наиболее частым методом является лучевая терапия. Другие методы воздействия применяются реже, один из них – необратимая электропорация (НЭП). Большая часть авторов указывают на приемлемый уровень осложнений и летальности, но без улучшения отдаленных результатов. Результаты двух метаанализов указывают на целесообразность применения метода у отобранных пациентов. Акцентируется внимание на том, что следует отдавать предпочтение малоинвазивным способам использования метода, поскольку накоплен определенный опыт применения чрескожного доступа для НЭП при МРРПЖ. Для навигации могут использоваться компьютерная томография, ультразвуковое наведение. Уровень осложнений достигает 50 %. Летальность при чрескожном доступе отсутствует или не превышает 5 %, отдаленные результаты не отличаются от результатов НЭП, выполненной во время лапаротомии.</p><p><bold>Цель исследования</bold> – оценка авторского опыта применения чрескожной НЭП при раке поджелудочной железы в виду отсутствия подобного опыта у коллег в России.</p><p><bold>Материалы и методы.</bold> Процедура чрескожной НЭП при раке поджелудочной железы выполнена у пациентки 53 лет по поводу МРРПЖ после успешной индукционной терапии. Осуществлялось поэтапное импульсное воздействие с помощью установленных под ультразвуковым контролем электродов на опухолевый инфильтрат. В диагностических целях применялись магнитно-резонансная томография, компьютерная томография и другие виды исследований.</p><p><bold>Результаты.</bold> Отмечено уменьшение размеров опухолевого инфильтрата после индукционной терапии при сохранении вовлечения общей печеночной артерии и полного блока воротной и верхней брыжеечной вен с развитием коллатералей, что не позволило выполнить панкреатодуоденальную резекцию. Ультразвуковая навигация с неоднократным контролем расположения электродов с помощью плоскодетекторной компьютерной томографии позволила адекватно и безопасно их установить, а в последующем – убедиться в отсутствии осложнений. Результаты магнитно-резонансной томографии, выполненной до и после процедуры, показали отсутствие прогрессирования заболевания в течение 3,5 мес после процедуры, в том числе в зоне воздействия. Отмечено уменьшение опухоли в рамках частичного ответа.</p><p><bold>Заключение.</bold> Подтверждены безопасность и отсутствие последующих осложнений при применении метода чрескожного доступа для НЭП при МРРПЖ. Наблюдение за пациенткой позволит более корректно высказаться о возможности метода обеспечить длительный локальный контроль заболевания при МРРПЖ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>unresectable non-metastatic pancreatic cancer</kwd><kwd>methods of local tumor destruction</kwd><kwd>combined therapy</kwd><kwd>flat-detector computed tomography</kwd><kwd>irreversible electroporation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>нерезектабельный неметастатический рак поджелудочной железы</kwd><kwd>методы локальной деструкции опухоли</kwd><kwd>комбинированная терапия</kwd><kwd>плоскодетекторная компьютерная томография</kwd><kwd>необратимая электропорация</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The consumables for electroporation were provided by REEPL.</funding-statement><funding-statement xml:lang="ru">Расходные материалы для электропорации предоставлены фирмой REEPL («РИПЛ»).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Heestand G.M., Murphy J.D., Lowy A.M. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;1;33(16):1770–8. PMID: 25918279. DOI: 10.1200/JCO.2014.59.7930</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Suker M., Beumer B.R., Sadot E. et al. Folfirinox for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016;17:801–10. PMID: 27160474. DOI: 10.1016/S1470-2045(16)00172-8</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Narayanan G., Daye D., Wilson N.M. et al. Ablation in Pancreatic</mixed-citation><mixed-citation xml:lang="ru">Narayanan G., Daye D., Wilson N.M. et al. Ablation in Pancreatic Cancer: Past, Present and Future. Cancers (Basel) 2021;13(11):2511. PMID: 34063784. DOI: 10.3390/cancers13112511</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Cancer: Past, Present and Future. Cancers (Basel) 2021;13(11):2511. PMID: 34063784. DOI: 10.3390/cancers13112511</mixed-citation><mixed-citation xml:lang="ru">Edd J.F., Horowitz L., Davalos R.V. et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53(7):1409–15. PMID: 16830945. DOI: 10.1109/TBME.2006.873745</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Edd J.F., Horowitz L., Davalos R.V. et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53(7):1409–15. PMID: 16830945. DOI: 10.1109/TBME.2006.873745</mixed-citation><mixed-citation xml:lang="ru">Narayanan G., Hosein P.J., Arora G. et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012;23(12):1613–21. PMID: 23177107. DOI: 10.1016/j.jvir.2012.09.012</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Narayanan G., Hosein P.J., Arora G. et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012;23(12):1613–21. PMID: 23177107. DOI: 10.1016/j.jvir.2012.09.012</mixed-citation><mixed-citation xml:lang="ru">Saad A.M., Turk T., Al-Husseini M.J., Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018;18(1):688. PMID: 29940910. DOI: 10.1186/s12885-018-4610-4</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Saad A.M., Turk T., Al-Husseini M.J., Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018;18(1):688. PMID: 29940910. DOI: 10.1186/s12885-018-4610-4</mixed-citation><mixed-citation xml:lang="ru">Balaban E.P., Mangu P.B., Khorana A.A. et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(22):2654–68. PMID: 27247216. DOI: 10.1200/JCO.2016.67.5561</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Balaban E.P., Mangu P.B., Khorana A.A. et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(22):2654–68. PMID: 27247216. DOI: 10.1200/JCO.2016.67.5561</mixed-citation><mixed-citation xml:lang="ru">Spiliopoulos S., Zurlo M.T., Casella A. et al. Current status of non-surgical treatment of locally advanced pancreatic cancer. World J Gastrointest Oncol 2021;13(12):2064–75. PMID: 35070042. DOI: 10.4251/wjgo.v13.i12.2064</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Spiliopoulos S., Zurlo M.T., Casella A. et al. Current status of non-surgical treatment of locally advanced pancreatic cancer. World J Gastrointest Oncol 2021;13(12):2064–75. PMID: 35070042. DOI: 10.4251/wjgo.v13.i12.2064</mixed-citation><mixed-citation xml:lang="ru">Hammel P., Huguet F., van Laethem J.L. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016;315(17): 1844–53. PMID: 27139057. DOI: 10.1001/jama.2016.4324</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Hammel P., Huguet F., van Laethem J.L. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016;315(17): 1844–53. PMID: 27139057. DOI: 10.1001/jama.2016.4324</mixed-citation><mixed-citation xml:lang="ru">Herman J.M., Chang D.T., Goodman K.A. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121(7):1128–37. PMID: 25538019. DOI: 10.1002/cncr.29161</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Herman J.M., Chang D.T., Goodman K.A. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121(7):1128–37. PMID: 25538019. DOI: 10.1002/cncr.29161</mixed-citation><mixed-citation xml:lang="ru">Reyngold M., O’Reilly E.M., Varghese A.M. et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 2021;7(5):735–8. PMID: 33704353. DOI: 10.1001/jamaoncol.2021.0057</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Reyngold M., O’Reilly E.M., Varghese A.M. et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 2021;7(5):735–8. PMID: 33704353. DOI: 10.1001/jamaoncol.2021.0057</mixed-citation><mixed-citation xml:lang="ru">Zeng X.L., Wang H.H., Meng M.B. et al. Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. Onco Targets Ther 2016;9:3985–92. PMID: 27418841. DOI: 10.2147/OTT.S102784</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Zeng X.L., Wang H.H., Meng M.B. et al. Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. Onco Targets Ther 2016;9:3985–92. PMID: 27418841. DOI: 10.2147/OTT.S102784</mixed-citation><mixed-citation xml:lang="ru">Al-Sakere B., Andre F., Bernat C. et al. Tumor ablation with irreversible electroporation. PloSone 2007;2(11):e1135. PMID: 17989772. DOI: 10.1371/journal.pone.0001135</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Al-Sakere B., Andre F., Bernat C. et al. Tumor ablation with irreversible electroporation. PloSone 2007;2(11):e1135. PMID: 17989772. DOI: 10.1371/journal.pone.0001135</mixed-citation><mixed-citation xml:lang="ru">Edelblute C.M., Hornef J., Burcus N.I. et al. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Sci Rep 2017;7(1): 11767. PMID: 28924200. DOI: 10.1038/s41598-017-12227-4</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Edelblute C.M., Hornef J., Burcus N.I. et al. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Sci Rep 2017;7(1): 11767. PMID: 28924200. DOI: 10.1038/s41598-017-12227-4</mixed-citation><mixed-citation xml:lang="ru">Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местнораспространенном раке поджелудочной железы. Исследования и практика в медицине 2018;5(2):86–99. DOI: 10.17709/2409-2231-2018-5-2-10</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Moskvicheva L.I., Petrov L.O., Sidorov D.V. The possibilities of modern methods of ablation in non-resectable locally advanced pancreatic cancer. Research and Practical Med J 2018;5(2):86–99. (In Russ.) DOI: 10.17709/2409-2231-2018-5-2-10</mixed-citation><mixed-citation xml:lang="ru">Wendler J.J., Fischbach K., Ricke J. et al. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol 2016;81:54–64. PMID: 26966472. DOI: 10.12659/PJR.896034</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Wendler J.J., Fischbach K., Ricke J. et al. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol 2016;81:54–64. PMID: 26966472. DOI: 10.12659/PJR.896034</mixed-citation><mixed-citation xml:lang="ru">Martin R.C. 2nd , Kwon D., Chalikonda S. et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015;262(3):486–94. PMID: 26258317. DOI: 10.1097/SLA.0000000000001441</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Martin R.C. 2nd , Kwon D., Chalikonda S. et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015;262(3):486–94. PMID: 26258317. DOI: 10.1097/SLA.0000000000001441</mixed-citation><mixed-citation xml:lang="ru">Vogel J.A., Rombouts S.J., de Rooij T. et al. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann Surg Oncol 2017;24(9):2734–43. PMID: 28560601. DOI: 10.1245/s10434-017-5900-9</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Vogel J.A., Rombouts S.J., de Rooij T. et al. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann Surg Oncol 2017;24(9):2734–43. PMID: 28560601. DOI: 10.1245/s10434-017-5900-9</mixed-citation><mixed-citation xml:lang="ru">Астахов Д.А., Панченков Д.Н., Иванов Ю.В и др. Необратимая электропорация при местно-распространенном раке поджелудочной железы. Анналы хирургической гепатологии 2018;23(2):59–68. DOI: 10.16931/1995-5464.2018259-68</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Astakhov D.A., Panchenkov D.N., Ivanov Yu.V. et al. Irreversible electroporation for locally advanced pancreatic cancer. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery 2018;23(2): 59–68. (In Russ.) DOI: 10.16931/1995-5464.2018259-68</mixed-citation><mixed-citation xml:lang="ru">Ruarus A.H., Vroomen L.G.P.H., Geboers B. et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology 2020;294(1):212–20. PMID: 31687922. DOI: 10.1148/radiol.2019191109</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Ruarus A.H., Vroomen L.G.P.H., Geboers B. et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology 2020;294(1):212–20. PMID: 31687922. DOI: 10.1148/radiol.2019191109</mixed-citation><mixed-citation xml:lang="ru">Yang P.C., Huang K.W., Pua U. et al. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer – A multi-institutional clinical study in Asia. Eur J Surg Oncol 2020;46(5):811–7. PMID: 31839436. DOI: 10.1016/j.ejso.2019.12.006</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Yang P.C., Huang K.W., Pua U. et al. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer – A multi-institutional clinical study in Asia. Eur J Surg Oncol 2020;46(5):811–7. PMID: 31839436. DOI: 10.1016/j.ejso.2019.12.006</mixed-citation><mixed-citation xml:lang="ru">Mansson C., Brahmstaedt R., Nilsson A. et al. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol 2016;42(9):1401–6. PMID: 26906114. DOI: 10.1016/j.ejso.2016.01.024</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Mansson C., Brahmstaedt R., Nilsson A. et al. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol 2016;42(9):1401–6. PMID: 26906114. DOI: 10.1016/j.ejso.2016.01.024</mixed-citation><mixed-citation xml:lang="ru">Lafranceschina S., Brunetti O., Delvecchio A. et al. Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers (Basel) 2019;11(11):1718. PMID: 31684186. DOI: 10.3390/cancers11111718</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Lafranceschina S., Brunetti O., Delvecchio A. et al. Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers (Basel) 2019;11(11):1718. PMID: 31684186. DOI: 10.3390/cancers11111718</mixed-citation><mixed-citation xml:lang="ru">Moris D., Machairas N., Tsilimigras D.I. et al. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Ann Surg Oncol 2019;26(6):1657–68. PMID: 30843163. DOI: 10.1245/s10434-019-07261-7</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><mixed-citation>Moris D., Machairas N., Tsilimigras D.I. et al. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Ann Surg Oncol 2019;26(6):1657–68. PMID: 30843163. DOI: 10.1245/s10434-019-07261-7</mixed-citation></ref></ref-list></back></article>
